Raise closed, search for fresh raises on Seedstage

Newark, DE

Developing a wearable device for early detection of diabetic retinopathy to prevent blindness.

• Mission: Developing a wearable diagnostic headset for the early detection of diabetic retinopathy, aiming to prevent blindness and improve eye health monitoring for diabetic patients.  
• Innovation: Offering a non-invasive, automatic diagnostic solution that can be used in primary care settings, enabling early detection before irreversible eye damage occurs.  
• Market Opportunity: Addressing the global diabetes epidemic, which affects over 400 million people, by providing an accessible tool for early retinal disease detection, particularly in underserved healthcare settings.  
• Healthcare Impact: Reducing the risk of vision loss among diabetic patients by enabling timely diagnosis and intervention, ultimately improving quality of life and reducing healthcare costs associated with late-stage eye diseases.  
• Business Model: Leveraging existing reimbursement codes and pursuing Medicare eligibility to integrate LucyDx’s technology into the healthcare system effectively, with plans for market introduction in 2024.  
• Funding Uses: Supporting product development, regulatory affairs, and operational capabilities to enhance the availability and accessibility of eye health monitoring for diabetic patients in the U.S. and internationally.

LucyDx is a pioneering medical technology company focused on developing a wearable diagnostic headset aimed at the early detection of diabetic retinopathy, a leading cause of blindness among adults with diabetes. Founded in early 2021, the company emerged from the FedTech Startup Studio and has since validated the demand for its innovative device through extensive interviews with healthcare professionals and patients.

The headset is designed to provide a non-invasive, automatic diagnostic solution that can be used in primary care settings, making it accessible for early detection before irreversible eye damage occurs. By leveraging existing reimbursement codes and pursuing Medicare eligibility, LucyDx aims to integrate its technology into the healthcare system effectively.

The company’s mission is to address the global diabetes epidemic, which affects over 400 million people, by providing a tool that can significantly reduce the risk of vision loss. With plans for market introduction in 2024, LucyDx is seeking funding to further its product development, regulatory affairs, and operational capabilities to enhance eye health monitoring for diabetic patients across the United States and beyond.

Company Info

LUCYDX develops technology for early detection of retinal diseases in diabetics to help preserve eyesight.

LUCYDX is a medical device and technology company focused on aiding diabetics in preserving their eyesight by early detection of retinal eye diseases. Their technology enables medical professionals to monitor and address retinal damage before it becomes irreversible. The company is currently offering investment opportunities through a Netcapital RegCF Offering, aiming to engage individuals interested in the future of wearable telehealth solutions. LUCYDX also emphasizes the importance of awareness and education regarding diabetic retinopathy, highlighting that many individuals are diagnosed too late for effective intervention. They provide resources such as scientific publications, events for learning and observation, and an integrated health app to support their mission of improving eye health for diabetics.